in

Survival Win for Pembrolizumab in Early Triple-Negative Breast Cancer

Source link : https://www.newshealth.biz/health-news/survival-win-for-pembrolizumab-in-early-triple-negative-breast-cancer/

PD-1 inhibition before and after surgery for high-risk early triple-negative breast cancer (TNBC) led to significant improvement in overall survival (OS), according to updated results from a large randomized trial. After a median follow-up of 75 months, the 5-year OS was 86.6% in patients who received pembrolizumab (Keytruda) before and after surgery compared with 81.7% […]

Author : News Health

Publish date : 2024-09-17 19:49:22

Copyright for syndicated content belongs to the linked Source.

Elder millennials face off against death. Guess who wins?

Exciting Headingley Event Showcases Advances in Disability Rights